The application for phase I trial of Reliance Life Sciences’ recombinant protein-based vaccine candidate will be reviewed by the Subject Expert Committee (SEC) on August 26.
Indian Daily
Bringing you you the latest news, opinions, headline, stories, trends & more in the country. Browse the site for up to date information on national, regional and world wide happenings from politics, business, economy, finance, sports, movies, lifestyle, travel, events, food and a lot more
